Thromboembolism with Immunomodulatory Agents in the Treatment of Multiple Myeloma

Singh, Anurag; Gajra, Ajeet
January 2011
Cardiovascular & Hematological Agents in Medicinal Chemistry;2011, Vol. 9 Issue 1, p7
Academic Journal
No abstract available.


Related Articles

  • Thromboembolism with Immunomodulatory Agents in the Treatment of Multiple Myeloma. Singh, Anurag; Gajra, Ajeet // Cardiovascular & Hematological Agents in Medicinal Chemistry;2011, Vol. 9 Issue 2, p7 

    No abstract available.

  • Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma. Huang, Shang-Yi; Lin, Chung-Wu; Lin, Hsiu-Hsia; Yao, Ming; Tang, Jih-Luh; Wu, Shang-Ju; Chen, Yao-Chang; Lu, Hsiao-Yun; Hou, Hsin-An; Chen, Chien-Yuan; Chou, Wen-Chien; Tsay, Woei; Chou, Sheng-Je; Tien, Hwei-Fang // Annals of Hematology;Aug2014, Vol. 93 Issue 8, p1371 

    Cereblon (CRBN) is essential for the anti-myeloma (MM) activity of immunomodulatory drugs (IMiDs), such as thalidomide and lenalidomide. However, the clinical implications of CRBN in MM patients are unclear. Using immunohistochemical (IHC) staining on paraffin-embedded bone marrow sections, the...

  • Maintenance treatment in multiple myeloma. Harousseau, J. L. // Annals of Oncology;Jun2008 Supplement 4, Vol. 19, piv54 

    The article discusses the maintenance treatment of multiple myeloma. It explains the use of interferon-α as a maintenance treatment after conventional chemotherapy. It discusses the clinical application of thalidomide as maintenance therapy after high-dose therapy. The article also highlights...

  • New treatments in multiple myeloma: beyond optimal treatment. Harousseau, J.-L. // Annals of Oncology;Jun2008 Supplement 5, Vol. 19, pv68 

    The article looks at novel treatments in multiple myeloma which were made possible by the introduction of thalidomide, its analogue lenalidomide, and bortezomib. It discusses the side effects of combining the three novel agents with several drugs. The article also discusses findings on...

  • Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide. Fischer, Eric S.; Böhm, Kerstin; Lydeard, John R.; Yang, Haidi; Stadler, Michael B.; Cavadini, Simone; Nagel, Jane; Serluca, Fabrizio; Acker, Vincent; Lingaraju, Gondichatnahalli M.; Tichkule, Ritesh B.; Schebesta, Michael; Forrester, William C.; Schirle, Markus; Hassiepen, Ulrich; Ottl, Johannes; Hild, Marc; Beckwith, Rohan E. J.; Harper, J. Wade; Jenkins, Jeremy L. // Nature;8/6/2014, Vol. 512 Issue 7512, p49 

    In the 1950s, the drug thalidomide, administered as a sedative to pregnant women, led to the birth of thousands of children with multiple defects. Despite the teratogenicity of thalidomide and its derivatives lenalidomide and pomalidomide, these immunomodulatory drugs (IMiDs) recently emerged as...

  • Les nouveaux médicaments du myélome. Moreau, P.; Hulin, C. // Oncologie;May2010, Vol. 12 Issue 5/6, p353 

    Le traitement du myélome multiple a considérablement changé dans la dernière décennie, avec un allongement très important de la survie des patients, dans toutes les tranches d’âge, grâce à l’utilisation de nouveaux agents thérapeutiques. Cette revue...

  • Lenalidomide and Dexamethasone Regimen for Multiple Myeloma. Waddell, J. Aubrey; Solimando, Jr, Dominic A. // Hospital Pharmacy;May2012, Vol. 47 Issue 5, p343 

    The article offers information on the preparation, dispensing, and administration of the lenalidomide and dexamethasone regimen for the treatment of multiple myeloma. It says that the two drugs should be stored at room temperature, and that they are both administered orally. It mentions several...

  • Lenalidomide in the treatment of multiple myeloma. Rao, Kamakshi V. // American Journal of Health-System Pharmacy;9/1/2007, Vol. 64 Issue 17, p1799 

    Purpose. The pharmacology, clinical use, adverse effects, dosage and administration, and cost of lenalidomide in the treatment of multiple myeloma (MM) are reviewed. Summary. Lenalidomide is an analogue of thalidomide and has been shown to be more potent than thalidomide in the stimulation of...

  • Biological Activity of Lenalidomide and Its Underlying Therapeutic Effects in Multiple Myeloma. Martiniani, Roberta; Di Loreto, Valentina; Di Sano, Chiara; Lombardo, Alessandra; Liberati, Anna Marina // Advances in Hematology;2012, p1 

    Lenalidomide is a synthetic compound derived by modifying the chemical structure of thalidomide. It belongs to the second generation of immunomodulatory drugs (IMiDs) and possesses pleiotropic properties. Even if lenalidomide has been shown to be active in the treatment of several hematologic...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics